Cargando…
Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs
PURPOSE: PEGylated liposomes are important drug carriers that can passively target tumor by enhanced permeability and retention (EPR) effect in neoplasm lesions. This study demonstrated that tumor burden determines the tumor uptake, and also the tumor response, in cancer treatment with PEGylated lip...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651236/ https://www.ncbi.nlm.nih.gov/pubmed/23675454 http://dx.doi.org/10.1371/journal.pone.0063078 |
_version_ | 1782269187585998848 |
---|---|
author | Lin, Yi-Yu Kao, Hao-Wen Li, Jia-Je Hwang, Jeng-Jong Tseng, Yun-Long Lin, Wuu-Jyh Lin, Ming-Hsien Ting, Gann Wang, Hsin-Ell |
author_facet | Lin, Yi-Yu Kao, Hao-Wen Li, Jia-Je Hwang, Jeng-Jong Tseng, Yun-Long Lin, Wuu-Jyh Lin, Ming-Hsien Ting, Gann Wang, Hsin-Ell |
author_sort | Lin, Yi-Yu |
collection | PubMed |
description | PURPOSE: PEGylated liposomes are important drug carriers that can passively target tumor by enhanced permeability and retention (EPR) effect in neoplasm lesions. This study demonstrated that tumor burden determines the tumor uptake, and also the tumor response, in cancer treatment with PEGylated liposomal drugs in a C26/tk-luc colon carcinoma-bearing mouse model. METHODS: Empty PEGylated liposomes (NanoX) and those encapsulated with VNB (NanoVNB) were labeled with In-111 to obtain InNanoX and InVNBL in high labeling yield and radiochemical purity (all >90%). BALB/c mice bearing either small (58.4±8.0 mm(3)) or large (102.4±22.0 mm(3)) C26/tk-luc tumors in the right dorsal flank were intravenously administered with NanoVNB, InNanoX, InVNBL, or NanoX as a control, every 7 days for 3 times. The therapeutic efficacy was evaluated by body weight loss, tumor growth inhibition (using calipers and bioluminescence imaging) and survival fraction. The scintigraphic imaging of tumor mouse was performed during and after treatment. RESULTS: The biodistribution study of InVNBL revealed a clear inverse correlation (r (2) = 0.9336) between the tumor uptake and the tumor mass ranged from 27.6 to 623.9 mg. All three liposomal drugs showed better therapeutic efficacy in small-tumor mice than in large-tumor mice. Tumor-bearing mice treated with InVNBL (a combination drug) showed the highest tumor growth inhibition rate and survival fraction compared to those treated with NanoVNB (chemodrug only) and InNanoX (radionuclide only). Specific tumor targeting and significantly increased tumor uptake after periodical treatment with InVNBL were evidenced by scintigraphic imaging, especially in mice bearing small tumors. CONCLUSION: The significant differences in the outcomes of cancer treatment and molecular imaging between animals bearing small and large tumors revealed that tumor burden is a critical and discriminative factor in cancer therapy using PEGylated liposomal drugs. |
format | Online Article Text |
id | pubmed-3651236 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-36512362013-05-14 Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs Lin, Yi-Yu Kao, Hao-Wen Li, Jia-Je Hwang, Jeng-Jong Tseng, Yun-Long Lin, Wuu-Jyh Lin, Ming-Hsien Ting, Gann Wang, Hsin-Ell PLoS One Research Article PURPOSE: PEGylated liposomes are important drug carriers that can passively target tumor by enhanced permeability and retention (EPR) effect in neoplasm lesions. This study demonstrated that tumor burden determines the tumor uptake, and also the tumor response, in cancer treatment with PEGylated liposomal drugs in a C26/tk-luc colon carcinoma-bearing mouse model. METHODS: Empty PEGylated liposomes (NanoX) and those encapsulated with VNB (NanoVNB) were labeled with In-111 to obtain InNanoX and InVNBL in high labeling yield and radiochemical purity (all >90%). BALB/c mice bearing either small (58.4±8.0 mm(3)) or large (102.4±22.0 mm(3)) C26/tk-luc tumors in the right dorsal flank were intravenously administered with NanoVNB, InNanoX, InVNBL, or NanoX as a control, every 7 days for 3 times. The therapeutic efficacy was evaluated by body weight loss, tumor growth inhibition (using calipers and bioluminescence imaging) and survival fraction. The scintigraphic imaging of tumor mouse was performed during and after treatment. RESULTS: The biodistribution study of InVNBL revealed a clear inverse correlation (r (2) = 0.9336) between the tumor uptake and the tumor mass ranged from 27.6 to 623.9 mg. All three liposomal drugs showed better therapeutic efficacy in small-tumor mice than in large-tumor mice. Tumor-bearing mice treated with InVNBL (a combination drug) showed the highest tumor growth inhibition rate and survival fraction compared to those treated with NanoVNB (chemodrug only) and InNanoX (radionuclide only). Specific tumor targeting and significantly increased tumor uptake after periodical treatment with InVNBL were evidenced by scintigraphic imaging, especially in mice bearing small tumors. CONCLUSION: The significant differences in the outcomes of cancer treatment and molecular imaging between animals bearing small and large tumors revealed that tumor burden is a critical and discriminative factor in cancer therapy using PEGylated liposomal drugs. Public Library of Science 2013-05-10 /pmc/articles/PMC3651236/ /pubmed/23675454 http://dx.doi.org/10.1371/journal.pone.0063078 Text en © 2013 Lin et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Lin, Yi-Yu Kao, Hao-Wen Li, Jia-Je Hwang, Jeng-Jong Tseng, Yun-Long Lin, Wuu-Jyh Lin, Ming-Hsien Ting, Gann Wang, Hsin-Ell Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs |
title | Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs |
title_full | Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs |
title_fullStr | Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs |
title_full_unstemmed | Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs |
title_short | Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs |
title_sort | tumor burden talks in cancer treatment with pegylated liposomal drugs |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651236/ https://www.ncbi.nlm.nih.gov/pubmed/23675454 http://dx.doi.org/10.1371/journal.pone.0063078 |
work_keys_str_mv | AT linyiyu tumorburdentalksincancertreatmentwithpegylatedliposomaldrugs AT kaohaowen tumorburdentalksincancertreatmentwithpegylatedliposomaldrugs AT lijiaje tumorburdentalksincancertreatmentwithpegylatedliposomaldrugs AT hwangjengjong tumorburdentalksincancertreatmentwithpegylatedliposomaldrugs AT tsengyunlong tumorburdentalksincancertreatmentwithpegylatedliposomaldrugs AT linwuujyh tumorburdentalksincancertreatmentwithpegylatedliposomaldrugs AT linminghsien tumorburdentalksincancertreatmentwithpegylatedliposomaldrugs AT tinggann tumorburdentalksincancertreatmentwithpegylatedliposomaldrugs AT wanghsinell tumorburdentalksincancertreatmentwithpegylatedliposomaldrugs |